ENDURANCE-5, 6 Study

ENDURANCE-5, 6 Study: glecaprevir/pibrentasvir in genotype 5 or 6

Asselah T. Lancet Gastroenterol Hepatol 2018; Nov 1 (Epub ahead of print)

Anti-HCV
Glecaprevir (ABT-493)
Pibrentasvir (ABT-530)
Genotype
5
6

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

  • GLE/PIB: 100/40 mg 3 tablets QD

Objective

  • SVR12 (HCV RNA < 15 IU/ml), by ITT

Baseline characteristics and SVR12

Virologic failures, N = 2

Safety and tolerability